A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumour Malignancies
This phase I trial studies the side effects of atezolizumab in treating patients with cancer
following adoptive cell transfer. Monoclonal antibodies, such as atezolizumab, may interfere
with the ability of tumour cells to grow and spread.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society